Lansoprazol Lanzogastro

Lansoprazole, the active ingredient in Lansoprazol Lanzogastro, is a proton pump inhibitor presented as an oral tablet for oral use. It treats acid‑related disorders such as gastro‑esophageal reflux disease, duodenal and gastric ulcers, and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Lansoprazol Lanzogastro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to reduce gastric acid production in several acid‑related conditions. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Duodenal ulcer: accelerates ulcer healing and reduces recurrence. - Gastric ulcer: promotes ulcer closure and prevents relapse. - Helicobacter pylori eradication (in combination therapy): enhances eradication rates when combined with antibiotics. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion.

Lansoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild pain or pressure in the head. - Diarrhea: loose, watery stools. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort or cramps in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or breathing difficulty. - Clostridioides difficile infection: persistent diarrhea with colitis. - Low magnesium levels: muscle cramps, irregular heartbeat, or seizures. - Bone fractures: increased risk of hip, wrist, or spine fractures with long‑term therapy.

Before prescribing Lansoprazol Lanzogastro, clinicians should consider several safety aspects. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate for osteoporosis: long‑term use can affect calcium absorption. - Review concomitant medications: may interact with drugs requiring gastric acidity. - Monitor electrolytes: prolonged therapy can lead to low magnesium. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Lansoprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption. - Antifungal ketoconazole or itraconazole: decreased bioavailability. - Clopidogrel: impaired activation, may reduce antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation. - Digoxin: possible rise in serum levels, watch for toxicity. - Iron supplements: reduced absorption, separate dosing.